Other Briefings
India’s Food Processing Industry in 2026: Growth Trends, PLI Impact, and Export Performance
India’s food processing industry in 2026 is expanding steadily, driven by PLI incentives, rising foreign direct investments, export growth, and strong domestic demand, positioning it as a key engine of value addition and employment.
New Compliance Rules for Exporters: DGFT Mandates Digital Certificate of Origin
India’s export compliance framework is undergoing a significant shift as the DGFT mandates fully digital issuance and stricter oversight of the Certificate of Origin (CoO). The amendments to FTP and HBP 2023 streamline verification and reinforce regulatory oversight.
TDS Compliance & DTAA Optimization: A Guide to India’s Income-tax Act, 2025 for FY 2026-27
A comprehensive guide to India’s new TDS regime in FY 2026-27 for businesses and foreign investors. Learn about withholding tax on debt, capital gains, and technical services under the Income-tax Act, 2025.
India’s Mandatory Halal Certification 2026: New Country List & I-CAS Compliance Deadlines
India has expanded the I-CAS Halal certification requirement to 20 additional markets, bringing the total number of covered export destinations to 35 as of 2026. Explore the newly added markets and implementation timelines for exporters.
Income Tax Assessment in India (2025-26): Scrutiny Timelines & New Reassessment Rules
Gain a clear understanding of the transition to the Income-tax Act, 2025, including the revised tax assessment framework, scrutiny timelines, and reassessment provisions.
OIDAR Compliance in India: GST Registration, NTOR Rules, and Key Risks for Digital Service Providers
Supplying digital services to India? Even a single B2C transaction can trigger GST registration—understand OIDAR rules, NTOR risks, and compliance requirements.
India’s Tax Compliance Deadlines for April & May
FY 2026-27 represents a transition in India’s tax compliance calendar, with the new framework taking effect April 1. Businesses and investors face a dual-responsibility period: closing out obligations for the previous year under the old law while adopting new reporting structures for current transactions.
US Pharma Tariff 2026: Decoding the 100% Patented Drug Levy and the Generic Exemption
The US administration under President Donald J. Trump has implemented a 100% tariff on patented pharma products to curb import dependence. While Indian generics are exempt for now, a one-year review and API onshoring rules signal long-term shifts.
